PrecisemAb Biotech

Executive Summary

PrecisemAb Biotech is a preclinical-stage Taiwanese biotechnology company developing conditionally-activated antibodies using its proprietary Universal Antibody Lock™ platform. This technology masks antibody binding until activation by proteases in the disease microenvironment, thereby enhancing selectivity and reducing on-target toxicity. The company’s pipeline includes PSM101, an EGFR-targeted antibody for solid tumors, and PSM915, a bispecific antibody targeting TNF-α and IL-1β for autoimmune diseases. Founded in 2021 and based in Taipei, PrecisemAb operates with 10–50 employees and is privately held. The company has not disclosed total funding or valuation. As a preclinical entity, its near-term value hinges on advancing lead programs toward IND-enabling studies and securing partnerships or financing. The Universal Antibody Lock™ platform offers a differentiated approach to improving therapeutic indices, potentially addressing key limitations in oncology and immunology. However, the early-stage nature and lack of publicly available data on platform validation or pipeline progress warrant cautious optimism.

Upcoming Catalysts (preview)

• Q1 2027IND-enabling studies completion for PSM10155% success
• Q4 2026Preclinical proof-of-concept data for PSM915 in autoimmune models65% success
• TBDPotential strategic partnership or licensing deal for Universal Antibody Lock™ platform30% success